This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Zanamivir

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Zanamivir is a specific inhibitor of influenza virus neuraminidase. Zanamivir is licensed for the treatment of influenza A and B.

In clinical trials Zanamivir:

  • has been shown to reduce the duration of major symptoms in a population of previously healthy patients who presented with symptoms of influenza during a documented epidemic
  • reduces duration of symptoms by 1 to 1.5 days
  • patients who presented early after the onset of influenza symptoms with a fever >= 37.8 degrees C or who were at high risk of complications had the most benefit (2)

Note that when influenza is active in a community 60-80% of patients with flu-like symptoms will have influenza. If there is not a influenza outbreak the accuracy of clinical

The summary of product characteristics should be consulted before prescribing this drug.



Zanamivir may be prescribed to at risk individuals when influenza is circulating in the community.

Reference:

  • (1) Drug and Therapeutics Bulletin (1999). "Zanamivir for influenza". 37(11), 81-4.
  • (2) Monto AS, Flemming DM, Henry D et al (1999). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis, 180, 254-61.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.